If you have been reading about Cardarine and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-27. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
The molecules that contribute vitamin E activity are four tocopherols and four tocotrienols, within each group of four identified by the prefixes alpha- (α-), beta- (β-), gamma- (γ-), and delta- (δ-). For alpha(α)-tocopherol each of the three "R" sites has a methyl group (CH3) attached. For beta(β)-tocopherol: R1 = methyl group, R2 = H, R3 = methyl group. For gamma(γ)-tocopherol: R1 = H, R2 = methyl group, R3 = methyl group. For delta(δ)-tocopherol: R1 = H, R2 = H, R3 = methyl group. The same configurations exist for the tocotrienols, except that the unsaturated side chain has three carbon-carbon double bonds whereas the tocopherols have a saturated side chain. (Esters such as alpha-tocopherol acetate are digested in the human body to yield the corresponding tocopherol.) Nutritional labeling only takes into account the α-tocopherol form because the human liver preferentially retains this form due to the structure of alpha-tocopherol transfer protein. This form is present in much higher amounts in blood plasma than other forms, and it is known to cover the dietary requirement of vitamin E. The other forms are not considered essential.
Charles Edward Moody, Deputy Chief Executive, Engineering and Marine Training Authority. For services to Training. Derek William Charles Morgan. For public service in Wales. Patricia Morris. For political service. John Robin Mulholland, Agricultural Estates Manager, Crown Estate Commissioners. Herbert Neville Nahapiet, Chief Executive, UK Detention Services. For services to Engineering and to the Construction Industry. Robert Livingston Nelson, Director, Dounreay, UKAEA. For services to the Nuclear Industry. Malcolm Terence Newman, Range E, Her Majesty's Treasury Joan Mary North. For political and public service Jean Nugent, Nursing Director, St. Helier Hospital, Carshalton, Surrey. For services to Health Care. Geoffrey James Osborne, lately Grade 7, Department of the Environment. Alfred David Owen, Trustee, Community Development Foundation. For services to the community in the West Midlands. Anthony Frederick Parker, lately Courts Administrator, Lord Chancellor's Department. Pamela Margaret Parker, Vice President, All England Women's Hockey Association. For services to Hockey. Alan Edward Parkinson, Officer in Charge, Board of Inland Revenue. David Romer Paton. For services to the community in Aberdeen. Professor Christopher Charles Payne, Chief Executive, Horticulture Research International. For services to Horticultural Research. Ann Philippa Pearce (Mrs Christie), Author. For services to Children's Literature. Anne Pegington, Secretary, Royal College of Nursing's Welsh Board. For services to Nursing in Wales. Howard Wesley Petch, Principal, Bishop Burton College.
A similar stele fragment (ES 1027), 57 centimeters high by 42 centimeters wide by 20 deep, depicting Naram-Sin was found a few miles north-east of Diarbekr, at Pir Hüseyin in a well, though this was not its original context. It is said to have been first found in Miyafarkin, a village about 75 kilometers northeast of Diarbekr. Fragments of an alabaster stele representing captives being led by Akkadian soldiers is sometimes attributed to Narim-Sin (or Rimush or Manishtushu) on stylistic grounds. In particular, it is considered as more sophisticated graphically than the steles of Sargon of Akkad or those of Rimush or Manishtushu. Two fragments (IM 55639 and IM 59205) are in the National Museum of Iraq, and one (MFA 66.89) is the Boston Museum. The stele is quite fragmentary, but attempts at reconstitution have been made. Depending on sources, the fragments were excavated in Wasit, al-Hay district, Wasit Governorate, or in Nasiriyah, both locations in Iraq. It is thought that the stele represents the result of the campaigns of Naram-Sin to Cilicia or Anatolia. This is suggested by the characteristics of the booty carried by the soldiers in the stele, especially the metal vessel carried by the main soldier, the design of which is unknown in Mesopotamia, but on the contrary well known in contemporary Anatolia.
She had formerly had the same symptoms of arsenical poison herself, and it was some time before she discovered it to be the mesmeric work of an enemy. Soon after her marriage her husband began to manifest the same symptoms and had since shown them from time to time; but was, with her help, always able to overcome them. A few weeks ago she observed that he did not look well, and when questioned he said that he was unable to get the idea of this arsenical poison out of his mind. He had been steadily growing worse ever since, but still had hoped to overcome the trouble until the last. After the death the body had turned black. A doctor performed an autopsy and showed Eddy her husband's diseased heart, but she responded by giving more interviews about mesmerism. Fraser wrote that the articles made Eddy a household name, a real-life version of the charismatic and beautiful Verena Tarrant in Henry James's The Bostonians (1885–1886), with her interest in spiritualism, women's rights and the mind cure. Shortly after the death, Eddy moved next door to 571 Columbus Avenue with several students. The following year, 1883, she founded the Journal of Christian Science (later called the Christian Science Journal), which spread news of her ideas across the United States.
David eventually returns to Lanford and tells Darlene he wants to reenter his children's lives. After sleeping together, both Darlene and David consider reconciling until Roseanne tells Darlene the reason David said he left their marriage. She says it would be bad for their children, who resent David being an absent father. At Dan's urging, David agrees to get his life settled before seeing the kids again. In The Conners, David is working at Trader Joe's and has moved in with a free-spirited woman named Blue. Darlene is furious to discover that during the kids' first weekend staying with David, Blue allowed Harris' boyfriend to sleep over and she lost her virginity. David defensively says he was working and was unaware, but Darlene demands he be a more attentive father. David eventually breaks up with Blue because she wants children. David and Darlene began sleeping together again while Darlene is also in a relationship with Ben. Darlene decides she wants to be with Ben, and she and David finally agree to divorce. Ben, already knowing the two were seeing each other, breaks up with Darlene, though he eventually forgives her. David began seeing a therapist, and, during a joint session with Darlene, reveals he feels Darlene never treated him as an equal and caused him to leave her. When David was first introduced to the series, his name was Kevin, though it was subsequently changed to David. While applying for college, he uses his full name, David Maurice Healy. As a show inside joke, Roseanne comments in Season 6, "David's not even his real name.
Sources: en.wikipedia.org
== Synopsis == Luo Zijun lives a peaceful life as a full-time housewife, yet is unaware of the cracks in her marriage. One day, her husband Chen Junsheng files for divorce, and she is shocked. After divorce, Luo Zijun heads back into the workforce with the help of her dear friend Tang Jing and He Han, both being white-collar workers and elites.
Primary structure Elzinga and co-workers first determined the complete peptide sequence for this type of actin in 1973, with later work by the same author adding further detail to the model. It contains 374 amino acid residues. Its N-terminus is highly acidic and starts with an acetyled aspartate in its amino group, while its C-terminus is alkaline and is formed by a phenylalanine preceded by a cysteine, which has a degree of functional importance. Both extremes are in close proximity within the I-subdomain. An anomalous Nτ-methylhistidine is located at position 73.
=== Pregnancy === The research into the safety of benzodiazepines during pregnancy is limited and it is recommended that use of benzodiazepines during pregnancy should be based on whether the benefits outweigh the risks. If chlordiazepoxide is used during pregnancy, the risks can be reduced via using the lowest effective dose and for the shortest time possible. Benzodiazepines should generally be avoided during the first trimester of pregnancy. Chlordiazepoxide and diazepam are considered to be among the safer benzodiazepines to use during pregnancy in comparison to other benzodiazepines. Possible adverse effects from benzodiazepine use during pregnancy include miscarriage, malformation, intrauterine growth retardation, functional deficits, carcinogenesis and mutagenesis. Caution is also advised during breast feeding as chlordiazepoxide passes into breast milk.
Sotagliflozin, sold under the brand name Inpefa among others, is a medication used to reduce the risk of death due to heart failure. It is an inhibitor of sodium-glucose cotransporter 1 and 2 (SGLT1/SGLT2 inhibitor). It is taken by mouth. The most common adverse reactions include urinary tract infection, volume depletion, diarrhea, and hypoglycemia.. In additions, concerns aboout diabetic ketoacidosis led to the USA'S Food & Drug Administration not approving sotagliflozin along with insulin for the emergency treatment of hyperglycemia. Similar concerns led to the drug's later withdrawal from the European Union. Sotagliflozin was approved for medical use in the European Union in April 2019, as Zynquista, for the treatment for type 1 diabetes, and in the United States in May 2023, to reduce the risk of death due to heart failure. The marketing authorization for sotagliflozin was withdrawn in the EU in August 2022, at the request of the marketing-authorization holder.
The C-terminal domain of some proteins has specialized functions. In humans, the CTD of RNA polymerase II typically consists of up to 52 repeats of the sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser. This allows other proteins to bind to the C-terminal domain of RNA polymerase in order to activate polymerase activity. These domains are then involved in the initiation of DNA transcription, the capping of the RNA transcript, and attachment to the spliceosome for RNA splicing.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.